Search
Ipilimumab
go.drugbank.com/drugs/DB06186ApprovedInvestigational[L12126] Ipilimumab was granted FDA approval on 25 March 2011.[L12126] … [L12126] Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Etonogestrel
go.drugbank.com/drugs/DB00294ApprovedInvestigational[A37184] The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.[L5692]
Insulin lispro
go.drugbank.com/drugs/DB00046ApprovedInvestigationalMarketed as the brand name product Humalog, insulin lispro begins to exert its effects within 15 minutes of subcutaneous administration, while peak levels occur 30 to 90 minutes after administration. … Due to its duration of action of around 5 hours, Humalog is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the
Mixtures: HUMALOG MIX 25 SUSPENSION FOR INJECTION 100 iu/ml, HUMALOG MIX 25 SUSPENSION FOR INJECTION 100 iu/mlProducts: HUMALOG 100 U/ML, HUMALOG INJECTION 100 iu/mlDotatate gallium Ga-68
go.drugbank.com/drugs/DB13925ApprovedInvestigationalWithdrawn[A31358] Dotatate gallium 68 was developed by Advanced Accelerator Applications USA, Inc. and FDA approved in June 1, 2016. … Ga-68 dotatate has a high affinity for somatostatin-2 receptor and it is rapidly excreted from the nontarget sites which gives it an ideal candidate for imaging neuroendocrine tumors.
Mannitol
go.drugbank.com/drugs/DB00742ApprovedInvestigationalOn October 30, 2020, mannitol was approved by the FDA as add-on maintenance therapy for the control of pulmonary symptoms associated with cystic fibrosis in adult patients and is currently marketed for … Mannitol is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables.
Synonyms: D-Mannitol, D-(-)-MannitolRecombinant stabilized RSV B prefusion F antigen
go.drugbank.com/drugs/DB18714ApprovedInvestigational[L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023. … [L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of
Oxyquinoline
go.drugbank.com/drugs/DB11145ApprovedInvestigationalVet approvedOxyquinoline is a heterocyclic phenol and derivative of quinoline with antiseptic, disinfectant, and pesticide properties. It is used as a stabilizer for hydrogen peroxide, where it is sometimes added in cosmetic products.
Mixtures: Trimo San, Trimo-SanAlefacept
go.drugbank.com/drugs/DB00092ApprovedWithdrawnImmunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells,...
Mitapivat
go.drugbank.com/drugs/DB16236ApprovedInvestigational[A245478] On January 5, 2026, the FDA also approved the use of in the treatment of anemia in adults with alpha- or beta-thalassemia, making it the first oral treatment for this condition.[L54953] … [A245478] On February 17, 2022, the FDA approved mitapivat as the first disease-modifying treatment for hemolytic anemia in adults with pyruvate kinase (PK) deficiency, a rare, inherited disorder leading
Volanesorsen
go.drugbank.com/drugs/DB15067ApprovedVolanesorsen is an antisense oligonucleotide that binds to apoC-III mRNA to prevent its translation. … [L16621] This drug is not commonly prescribed as it is used as an adjunct to diet in patients at high risk for pancreatitis, who have had inadequate response to triglyceride lowering therapy.